CYPHERPUNK TECHNOLOGIES INC. Earnings Per Share (Basic)
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Earnings Per Share (Basic) of $0.21 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for the quarter ending 2026-06-30 was $0.21.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.46.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for the quarter ending 2025-12-31 was $0.29.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.08.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for fiscal 2025 was $0.07.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for fiscal 2024 was -$1.81.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for fiscal 2023 was -$3.98.
- CYPHERPUNK TECHNOLOGIES INC. earnings per share, basic for fiscal 2022 was -$4.82.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.21 10-Q · filed 2026-08-12 | -$0.21 10-Q · filed 2026-08-12 | $0.01 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2026-03-31 | -$0.46 10-Q · filed 2026-05-14 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-12-31 | $0.29 derived: net income ÷ weighted average shares · filed 2026-03-16 | $0.41 derived: net income ÷ weighted average shares · filed 2026-03-16 | $0.27 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.07 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$0.08 10-Q · filed 2025-11-12 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.85 10-Q · filed 2025-11-12 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-06-30 | -$0.40 10-Q · filed 2026-08-12 | -$0.78 10-Q · filed 2026-08-12 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.59 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-03-31 | -$0.37 10-Q · filed 2026-05-14 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-05-14 | ||||
| 2024-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$1.81 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | -$0.44 10-Q · filed 2025-11-12 | -$0.96 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.44 10-Q · filed 2025-11-12 | -$1.93 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2024-06-30 | -$0.52 10-Q · filed 2025-08-14 | -$1.01 10-Q · filed 2025-08-14 | -$1.50 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-08-14 | ||||
| 2024-03-31 | -$0.51 10-Q · filed 2025-05-13 | -$0.97 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$1.48 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$2.23 derived: net income ÷ weighted average shares · filed 2025-05-13 | ||||
| 2023-12-31 | -$0.46 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$0.97 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$1.73 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$3.98 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | -$0.51 10-Q · filed 2024-11-13 | -$1.30 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$3.78 10-Q · filed 2024-11-13 | -$4.92 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-06-30 | -$0.91 10-Q · filed 2024-08-12 | -$4.01 10-Q · filed 2024-08-12 | -$5.19 derived: net income ÷ weighted average shares · filed 2024-08-12 | -$6.56 derived: net income ÷ weighted average shares · filed 2024-08-12 | ||||
| 2023-03-31 | -$3.24 10-Q · filed 2024-05-13 | -$0.32 10-Q · filed 2023-05-15 | -$4.45 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$5.82 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$7.34 derived: net income ÷ weighted average shares · filed 2024-05-13 | |||
| 2022-12-31 | -$1.07 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$2.40 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$3.90 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$4.82 10-K · filed 2024-03-18 | -$0.48 10-K · filed 2023-03-24 | |||
| 2022-09-30 | -$1.33 10-Q · filed 2023-11-13 | -$0.13 10-Q · filed 2022-11-14 | -$2.84 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$3.75 10-Q · filed 2023-11-13 | -$0.38 10-Q · filed 2022-11-14 | -$0.85 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||
| 2022-06-30 | -$1.50 10-Q · filed 2023-08-14 | -$0.15 10-Q · filed 2022-08-12 | -$2.42 10-Q · filed 2023-08-14 | -$0.24 10-Q · filed 2022-08-12 | -$0.48 derived: net income ÷ weighted average shares · filed 2023-08-14 | -$0.62 derived: net income ÷ weighted average shares · filed 2023-08-14 | ||
| 2022-03-31 | -$0.09 10-Q · filed 2023-05-15 | -$0.19 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.32 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-05-15 | ||||
| 2021-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2023-03-24 | -$0.23 derived: net income ÷ weighted average shares · filed 2023-03-24 | -$0.35 derived: net income ÷ weighted average shares · filed 2023-03-24 | -$0.47 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | -$0.14 10-Q · filed 2022-11-14 | -$0.27 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.39 10-Q · filed 2022-11-14 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2021-06-30 | -$0.12 10-Q · filed 2022-08-12 | -$0.24 10-Q · filed 2022-08-12 | -$0.33 derived: net income ÷ weighted average shares · filed 2022-08-12 | -$0.42 derived: net income ÷ weighted average shares · filed 2022-08-12 | ||||
| 2021-03-31 | -$0.12 10-Q · filed 2022-05-13 | -$0.21 derived: net income ÷ weighted average shares · filed 2022-05-13 | -$0.30 derived: net income ÷ weighted average shares · filed 2022-05-13 | -$0.42 derived: net income ÷ weighted average shares · filed 2022-05-13 | ||||
| 2020-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$0.18 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$0.30 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$0.63 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | -$0.09 10-Q · filed 2020-11-12 | -$0.21 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.58 10-Q · filed 2020-11-12 | -$0.84 derived: net income ÷ weighted average shares · filed 2021-11-12 | ||||
| 2020-06-30 | -$0.12 10-Q · filed 2020-08-13 | -$0.57 10-Q · filed 2020-08-13 | -$0.88 derived: net income ÷ weighted average shares · filed 2021-08-13 | -$1.20 derived: net income ÷ weighted average shares · filed 2021-08-13 | ||||
| 2020-03-31 | -$0.55 10-Q · filed 2020-05-14 | -$0.91 derived: net income ÷ weighted average shares · filed 2021-05-14 | -$1.25 derived: net income ÷ weighted average shares · filed 2021-05-14 | -$1.62 derived: net income ÷ weighted average shares · filed 2021-05-14 | ||||
| 2019-12-31 | -$0.33 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$0.66 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.03 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.47 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | -$0.33 10-Q · filed 2020-11-12 | -$0.70 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$1.15 10-Q · filed 2020-11-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2020-11-12 | ||||
| 2019-06-30 | -$0.37 10-Q · filed 2020-08-13 | -$0.82 10-Q · filed 2020-08-13 | -$0.84 derived: net income ÷ weighted average shares · filed 2020-08-13 | -$1.26 derived: net income ÷ weighted average shares · filed 2020-08-13 | ||||
| 2019-03-31 | -$0.47 10-Q · filed 2020-05-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2020-05-14 | -$0.87 derived: net income ÷ weighted average shares · filed 2020-05-14 | |||||
| 2018-12-31 | $0.10 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$0.35 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$1.64 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | -$0.45 10-Q · filed 2019-11-14 | -$1.76 10-Q · filed 2019-11-14 | ||||||
| 2017-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2019-04-01 | -$1.32 derived: net income ÷ weighted average shares · filed 2019-04-01 | -$3.27 10-K · filed 2019-04-01 | |||||
| 2017-09-30 | -$0.73 10-Q · filed 2018-11-09 | -$2.72 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |